In summary, throughout the last 10 years probably the most amazing advantage has become attained in HER2/neu-overexpressing MBC. Introduction of bevacizumab for a VEGF-directed qualified treatment continues to be a concern on discussion. A lot of the novel therapeutics towards the breast cancer armamentarium resulted in prolongation of survival for